Zhao Jinlong, Huang Hetao, Liang Guihong, Zeng Ling-Feng, Yang Weiyi, Liu Jun
The Second School of clinical medical Sciences, Guangzhou University of Chinese Medicine, Guagnzhou, 510405, China.
Guangdong Academy of Traditional Chinese Medicine, Research Team on Bone and Joint Degeneration and Injury, Guangzhou, 510120, China.
BMC Musculoskelet Disord. 2020 Apr 11;21(1):224. doi: 10.1186/s12891-020-03262-w.
Studies have shown that the combined application of hyaluronic acid (HA) and platelet-rich plasma (PRP) can repair degenerated cartilage and delay the progression of knee osteoarthritis (KOA). The purpose of this study was to explore the efficacy and safety of the intra-articular injection of PRP combined with HA compared with the intra-articular injection of PRP or HA alone in the treatment of KOA.
The PubMed, Cochrane Library, EMBASE and China National Knowledge Infrastructure (CNKI) databases were searched from inception to December 2019. Randomized controlled trials and cohort studies of PRP combined with HA for KOA were included. Two orthopaedic surgeons conducted the literature retrieval and extracted the data. Outcome indicators included the Western Ontario and McMaster Universities Arthritis Index (WOMAC), the Lequesne Index, the visual analogue scale (VAS) for pain, and adverse events (AEs). Review Manager 5.3 was used to calculate the relative risk (RR) or standardized mean difference (SMD) of the pooled data. STATA 14.0 was used for quantitative publication bias evaluation.
Seven studies (5 randomized controlled trials, 2 cohort studies) with a total of 941 patients were included. In the VAS comparison after 6 months of follow-up, PRP combined with HA was more likely to reduce knee pain than PRP alone (SMD: - 0.31; 95% confidence interval (CI): - 0.55 to - 0.06; P = 0.01 < 0.05). PRP combined with HA for KOA achieved better improvements in the WOMAC Function Score (SMD: -0.32; 95% CI: - 0.54 to - 0.10; P < 0.05) and WOMAC Total Score (SMD: -0.42; 95% CI: - 0.67 to - 0.17; P < 0.05) at the 12-month follow-up than did the application of PRP alone. In a comparison of Lequesne Index scores at the 6-month follow-up, PRP combined with HA improved knee pain scores more than PRP alone (SMD: -0.42; 95% CI: - 0.67 to - 0.17; P < 0.05). In terms of AEs, PRP combined with HA was not significantly different from PRP or HA alone (P > 0.05).
Compared with intra-articular injection of PRP alone, that of PRP combined with HA can improve the WOMAC Function Scores, WOMAC Total Score, 6-month follow-up VAS ratings, and Lequesne Index scores. However, in terms of the incidence of AEs, PRP combined with HA is not significantly different from PRP or HA alone.
研究表明,透明质酸(HA)与富血小板血浆(PRP)联合应用可修复退变软骨并延缓膝关节骨关节炎(KOA)的进展。本研究旨在探讨关节腔内注射PRP联合HA与单独关节腔内注射PRP或HA治疗KOA的疗效及安全性。
检索PubMed、Cochrane图书馆、EMBASE和中国知网(CNKI)数据库,检索时间从建库至2019年12月。纳入PRP联合HA治疗KOA的随机对照试验和队列研究。两名骨科医生进行文献检索并提取数据。结局指标包括西安大略和麦克马斯特大学骨关节炎指数(WOMAC)、Lequesne指数、疼痛视觉模拟量表(VAS)以及不良事件(AE)。使用Review Manager 5.3计算合并数据的相对危险度(RR)或标准化均数差(SMD)。使用STATA 14.0进行定量发表偏倚评估。
共纳入7项研究(5项随机对照试验,2项队列研究),总计941例患者。在随访6个月后的VAS比较中,PRP联合HA比单独使用PRP更有可能减轻膝关节疼痛(SMD:-0.31;95%置信区间(CI):-0.55至-0.06;P = 0.01 < 0.05)。在12个月随访时,PRP联合HA治疗KOA在WOMAC功能评分(SMD:-0.32;9% CI:-0.54至-0.10;P < 0.05)和WOMAC总分(SMD:-0.42;95% CI:-0.67至-0.17;P < 0.05)方面比单独应用PRP有更好的改善。在6个月随访时Lequesne指数评分的比较中,PRP联合HA比单独使用PRP更能改善膝关节疼痛评分(SMD:-0.42;95% CI:-0.67至-0.17;P < 0.05)。在不良事件方面,PRP联合HA与单独使用PRP或HA无显著差异(P > 0.05)。
与单独关节腔内注射PRP相比,PRP联合HA关节腔内注射可改善WOMAC功能评分、WOMAC总分、6个月随访时的VAS评分以及Lequesne指数评分。然而,在不良事件发生率方面,PRP联合HA与单独使用PRP或HA无显著差异。